Physician profile
Eric S Schaefer
NPI 1558325118
$465,814.48
in general payments reported to CMS, 2019-2025
94 companies · $148K in 2025
The $148K reported for 2025 was more than what 99% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $2,376 · 2020: $34K · 2021: $24K · 2022: $76K · 2023: $119K · 2024: $61K · 2025: $148K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $125K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $83K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $51K · Honoraria: $50K · Travel and Lodging: $10K · Food and Beverage: $9,510 · Education: $48.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $124,893.25 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $82,949.25 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $50,735.00 |
| Honoraria | $49,692.00 |
| Travel and Lodging | $10,490.28 |
| Food and Beverage | $9,509.72 |
| Education | $48.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cornerstone Specialty Network LLC | $242,517.00 | 2022-2025 | |
| Daiichi Sankyo INC. | $104,566.24 | 2020-2025 | Enhertu, Datroway, Vanflyta |
| Onmark, INC. | $26,921.94 | 2022-2025 | |
| Amgen INC. | $19,201.25 | 2019-2024 | Lumakras, Kyprolis, Blincyto |
| Astrazeneca Pharmaceuticals LP | $13,912.66 | 2019-2025 | Lynparza, Imfinzi, Tagrisso |
| Sanofi US Services INC. | $6,710.95 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $5,180.10 | 2019-2024 | Opdivo, Eliquis |
| Regeneron Healthcare Solutions, INC. | $4,739.88 | 2019-2025 | Libtayo |
| Blueprint Medicines Corporation | $4,604.78 | 2020-2025 | Ayvakit |
| Taiho Oncology, INC. | $2,840.18 | 2019-2024 | |
| Glaxosmithkline, LLC. | $2,837.29 | 2020-2025 | Ojjaara |
| Exelixis INC. | $2,821.86 | 2019-2025 | Cabometyx |
| Janssen Biotech, INC. | $2,420.23 | 2019-2025 | Erleada, Rybrevant, Carvykti |
| Genzyme Corporation | $2,401.99 | 2019-2025 | |
| Emd Serono, INC. | $2,287.38 | 2019-2025 | Tepmetko |
Show all 89 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,147.12 | 2019-2025 | |
| Jazz Pharmaceuticals INC. | $1,671.98 | 2019-2025 | |
| Seagen INC. | $1,429.31 | 2020-2022 | |
| Beigene, LTD. | $1,402.50 | 2020-2021 | |
| Tg Therapeutics, INC. | $1,360.71 | 2021 | |
| Heron Therapeutics, INC. | $1,312.55 | 2020 | |
| Athenex Pharmaceutical Division, LLC | $1,250.00 | 2020 | |
| Janssen Scientific Affairs, LLC | $1,206.20 | 2023-2025 | Rybrevant, Darzalex, Tecvayli |
| Aveo Pharmaceuticals, INC. | $1,199.78 | 2022-2024 | Fotivda |
| Coherus Oncology, INC. | $900.00 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $757.62 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $751.53 | 2019-2025 | Gilotrif |
| Janssen Global Services, LLC | $575.00 | 2025 | Tecvayli |
| Merck Sharp & Dohme LLC | $571.19 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Alexion Pharmaceuticals, INC. | $400.00 | 2019-2022 | |
| Celgene Corporation | $368.54 | 2019-2023 | Opdualag, Reblozyl, Pomalyst |
| Janssen Pharmaceuticals, INC | $368.31 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $253.73 | 2019-2025 | Fruzaqla |
| Genentech USA, INC. | $240.14 | 2019-2025 | Tecentriq, Alecensa |
| Novocure Gmbh | $200.00 | 2022 | |
| Lilly USA, LLC | $198.55 | 2019-2025 | Retevmo, Jaypirca, Verzenio |
| Caris Mpi, INC. | $195.54 | 2025 | Mi Cancer Seek |
| Ipsen Biopharmaceuticals, INC | $194.88 | 2020-2025 | Onivyde, Tazverik, Somatuline Depot |
| Intuitive Surgical, INC. | $194.88 | 2023 | Da Vinci Surgical System |
| Beigene USA, INC. | $187.37 | 2020-2024 | Brukinsa |
| Pfizer INC. | $184.39 | 2019-2025 | |
| Eisai INC. | $154.42 | 2020-2025 | |
| Astellas Pharma US INC | $148.78 | 2019-2023 | Padcev, Xospata |
| Gilead Sciences, INC. | $128.33 | 2019-2024 | |
| Incyte Corporation | $116.26 | 2019-2025 | Monjuvi, Jakafi |
| Kite Pharma, INC. | $105.62 | 2019-2023 | |
| Array Biopharma INC | $103.63 | 2019-2025 | Lorbrena, Braftovi, Mektovi |
| Comsort, INC | $100.00 | 2019 | |
| Amneal Pharmaceuticals LLC | $94.68 | 2025 | Pemrydi Rtu |
| Sumitomo Pharma America, INC. | $84.95 | 2023-2025 | Orgovyx, Gemtesa |
| Kyowa Kirin, INC. | $84.26 | 2020-2022 | |
| Pharmacosmos Therapeutics INC. | $68.27 | 2023-2025 | Monoferric, Cosela |
| G1 Therapeutics, INC. | $65.87 | 2022-2023 | Cosela |
| Puma Biotechnology, INC. | $63.92 | 2019-2024 | |
| Pharmacyclics LLC, An Abbvie Company | $63.26 | 2019-2023 | Epkinly |
| Mirati Therapeutics, INC. | $62.22 | 2024 | Krazati |
| Sobi, INC | $60.38 | 2023-2025 | |
| Tesaro, INC. | $54.57 | 2019 | |
| Foundation Medicine, INC. | $52.72 | 2019 | |
| Cardinal Health 110 LLC | $51.94 | 2024 | |
| Karyopharm Therapeutics INC. | $51.48 | 2020-2022 | |
| Verastem, INC. | $48.28 | 2019 | |
| Blue Earth Diagnostics | $36.71 | 2021-2022 | |
| Abbvie INC. | $34.49 | 2024-2025 | |
| US Oncology Corporate, INC. | $31.05 | 2025 | |
| Epizyme, INC. | $30.20 | 2020 | |
| Morphosys, US INC. | $28.03 | 2023 | Monjuvi |
| Nuvation Bio INC. | $27.63 | 2025 | Ibtrozi |
| Dendreon Pharmaceuticals LLC | $25.86 | 2021-2024 | Provenge |
| Rigel Pharmaceuticals, INC. | $25.36 | 2023 | Tavalisse, Rezlidhia |
| The Binding Site INC. | $25.00 | 2020 | |
| Alnylam Pharmaceuticals INC. | $24.16 | 2021-2023 | Givlaari |
| Agios Pharmaceuticals, INC. | $23.20 | 2019-2020 | |
| Apellis Pharmaceuticals, INC. | $22.88 | 2023 | Empaveli |
| Progenics Pharmaceuticals, INC. | $21.09 | 2024 | |
| Tempus Ai, INC | $20.60 | 2024 | |
| Secura Bio, INC. | $19.33 | 2019-2022 | |
| Clovis Oncology, INC. | $18.62 | 2020 | |
| Telix Pharmaceuticals | $17.35 | 2022 | |
| Genmab U.S., INC. | $15.99 | 2025 | Epkinly |
| Curium US LLC | $15.74 | 2021 | |
| Syndax Pharmaceuticals, INC. | $15.47 | 2025 | |
| Dova Pharmaceuticals | $14.27 | 2020 | |
| Cti Biopharma Corp. | $13.95 | 2022 | |
| Helsinn Therapeutics (U.S.), INC. | $12.96 | 2019 | |
| Tersera Therapeutics LLC | $12.15 | 2022 | |
| Acceleron Pharma, INC. | $12.05 | 2020 | |
| Aurobindo Pharma USA, INC. | $11.89 | 2019 | |
| Fortovia Therapeutics, INC. | $9.06 | 2019 |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$2,935.00 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
$103,250.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Schaefer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.